Page last updated: 2024-12-05

glycerylphosphorylcholine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Glycerylphosphorylcholine (GPC) is a naturally occurring phospholipid that is found in high concentrations in the brain and other tissues. It is a precursor to the neurotransmitter acetylcholine, and is thought to play a role in learning, memory, and cognitive function. GPC is synthesized in the body from the breakdown of phosphatidylcholine. Research suggests that GPC may have therapeutic potential for a variety of conditions, including Alzheimer's disease, Parkinson's disease, and stroke. It has been shown to improve cognitive function in animal models of these diseases, and is currently being investigated in clinical trials. GPC is also being studied for its potential to improve athletic performance and reduce muscle fatigue.'

Glycerylphosphorylcholine: A component of PHOSPHATIDYLCHOLINES or LECITHINS, in which the two hydroxy groups of GLYCEROL are esterified with fatty acids. (From Stedman, 26th ed) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

choline alfoscerate : A member of the class of phosphocholines that is the choline ester of sn-glycero-3-phosphate. It is one of the major osmolyte in the renal medullary cells. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

glycerophosphocholine : The glycerol phosphate ester of a phosphocholine. A nutrient with many different roles in human health. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11234
CHEBI ID135063
SCHEMBL ID245306
MeSH IDM0009450
PubMed CID657272
CHEMBL ID1567463
CHEBI ID16870
CHEBI ID55397
SCHEMBL ID63754
MeSH IDM0009450

Synonyms (123)

Synonym
G-4205
glycerylphosphorylcholine
CHEBI:135063
2,3-dihydroxypropyl 2-(trimethylazaniumyl)ethyl phosphate
563-24-6
ethanaminium, 2-(((2,3-dihydroxypropoxy)hydroxyphosphinyl)oxy)-n,n,n-trimethyl-, inner salt
4217-84-9
l-|a-glycerylphosphorylcholine(gpc)
AKOS015965125
FT-0627676
HMS3372C09
SCHEMBL245306
glycerylphosphorylcholin
(r)-2-[[(2,3-dihydroxypropoxy)hydroxyphosphinyl]oxy]-n,n,n-trimethylethanaminium inner salt
2,3-dihydroxypropyl 2-(trimethylammonio)ethyl phosphate
STL453195
mfcd00063544
Q47038648
choline alfoscerate (not stereospecific)
SY046440
BCP09818
HY-W096638
CS-0158915
2,3-dihydroxypropyl (2-(trimethylammonio)ethyl) phosphate
2-{[(2r)-2,3-dihydroxypropoxy](hydroxy)phosphoryloxy}-n,n,n-trimethylethanaminium
glycerophosphate de choline
alpha-glycerophosphorylcholine
alfoscerate de choline
l-choline hydroxide 2,3-dihydroxypropyl hydrogen phosphate inner salt
glycerol-3-phosphocholine
sn-glycerol 3-phosphocholine
glycerophosphorylcholine
gpcho
(2r)-2,3-dihydroxypropyl 2-(trimethylazaniumyl)ethyl phosphate
CHEBI:16870 ,
l-alpha-glycerophosphocholine
cholini alfosceras
glicerofosfato de colina
glycerol phosphorylcholine
alfoscerato de colina
choline alfoscerate
l-alpha-glycerophosphorylcholine
glycerol-3-phosphatidylcholine
choline glycerophosphate
choline alphoscerate
(2r)-2,3-dihydroxypropyl 2-(trimethylammonio)ethyl phosphate
cholini glycerophosphas
ethanaminium, 2-(((2,3-dihydroxypropoxy)hydroxyphosphinyl)oxy)-n,n,n-trimethyl-, hydroxide, inner salt, (r)-
glicerofosfato de colina [spanish]
choline alfoscerate [inn]
cholini alfosceras [inn-latin]
choline hydroxide, (r)-2,3-dihydroxypropyl hydrogen phosphate, inner salt
choline, hydroxide, 2,3-dihydroxypropyl hydrogen phosphate, inner salt, d-
glycerophosphate de choline [french]
cholini glycerophosphas [latin]
einecs 248-962-2
calcium (glycerophosphate de) [dcf]
brn 6062450
l-alpha-glycerylphosphorylcholine
alfoscerate de choline [inn-french]
colina glicerofosfato
alfoscerato de colina [inn-spanish]
choline alfoscerate (inn)
gliatilin (tn)
D07349
glycero-phosphocholine
l-1-glycero-3-phosphocholine
glycerophosphocholine
28319-77-9
L-1-GLYCERO-PHOSPHORYLCHOLINE
sn-3-gpc
sn-glycero-3-phosphocholine
DB04660
smr000058753
MLS000069588 ,
glycerol 3-phosphocholine
l-a-glycerophosphorylcholine
AKOS005762883
HMS2233P21
60m22sgw66 ,
alpha-glyceryl phosphoryl choline
calcium (glycerophosphate de)
unii-60m22sgw66
CHEMBL1567463
gliatilin
alpha-glycerylphosphorylcholine
ethanaminium,2-[[[(2r)-2,3-dihydroxypropoxy]hydroxyphosphinyl]oxy]-n,n,n-trimethyl-, innersalt
EPITOPE ID:150907
chebi:55397
choline alfoscerate [mi]
choline alfoscerate [mart.]
glycerophosphocholine [inci]
l-alpha-glycerylphosphorylcholine [usp-rs]
ethanaminium, 2-((((2r)-2,3-dihydroxypropoxxy)hydroxyphosphinyl)oxy)-n,n,n-trimethyl-, inner salt
choline alfoscerate [who-dd]
l-.alpha.-glycerylphosphorylcholine
HY-17552
SCHEMBL63754
(r)-2,3-dihydroxypropyl (2-(trimethylammonio)ethyl) phosphate
OPERA_ID_471
EX-A979
H10892
brezal
2-[[(2,3-dihydroxypropoxy)hydroxyphosphinyl]oxy]-n,n,n-trimethyl-ethanaminium inner salt
a-glycerylphosphorylcholine
hydrogen glycerophosphate choline
glycerophosphatidylcholine
a-glycerophosphorylcholine
choline alfoscerate;l--gpc;l--lecithin
Q28529699
(2-{[(2r)-2,3-dihydroxypropyl phosphonato]oxy}ethyl)trimethylazanium
SUHOQUVVVLNYQR-MRVPVSSYSA-N
AS-13724
(r)-2,3-dihydroxypropyl 2-(trimethylammonio)ethyl phosphate
HMS3887O13
AMY40024
CCG-267031
sn-glycerophosphorylcholine (egg, free base)
AC7982
alpha-gpc
l-a-gpc
DTXSID70951010
glycerylphosphorylcholine;cholini alfosceras

Research Excerpts

Overview

L-α-Glycerylphosphorylcholine is a biosynthetic precursor for the neurotransmitter acetylcholine in humans. It is a useful as a cognitive enhancer for treating patients with stroke and dementia, including Alzheimer's disease.

ExcerptReferenceRelevance
"l-α-Glycerylphosphorylcholine (l-α-GPC) is a biosynthetic precursor for the neurotransmitter acetylcholine in humans, making it a useful as a cognitive enhancer for treating patients with stroke and dementia, including Alzheimer's disease. "( Enzymatic preparation of food-grade l-α-glycerylphosphorylcholine from soy phosphatidylcholine or fractionated soy lecithin.
Chung, MY; Kim, BH; Kim, IH; Kim, J; Lee, JE; Lee, SJ; Song, Y, 2020
)
1.38
"α-Glycerylphosphorylcholine (AGPC) is a semi-synthetic derivative of lecithin. "( Safety assessment of AGPC as a food ingredient.
Brownawell, AM; Carmines, EL; Montesano, F, 2011
)
1.09

Toxicity

ExcerptReferenceRelevance
" The biocompatibility of synthesized segmented polyurethanes was then investigated by platelet-rich plasma contact studies and related scanning electron microscopy (SEM) photographs for blood compatibility and cytotoxicity assay (MTT test) on material elution to assess the effect of any toxic leachables on cellular viability."( Synthesis, platelet adhesion and cytotoxicity studies of new glycerophosphoryl-containing polyurethanes.
D'Arrigo, P; Giordano, C; Macchi, P; Malpezzi, L; Pedrocchi-Fantoni, G; Servi, S, 2007
)
0.34
" The oral LD50 was equal to or greater than 10,000 mg/kg in rats and mice."( Safety assessment of AGPC as a food ingredient.
Brownawell, AM; Carmines, EL; Montesano, F, 2011
)
0.37
"The drug is well-tolerated and safe and can be recommended for preventive treatment of dementia in patients with high AD risk, in particular in elderly patients with aMCI syndrome."( [Clinical efficacy and safety of choline alfoscerate in the treatment of late-onset cognitive impairment].
Fedorova, YB; Gavrilova, SI; Kolykhalov, IV; Ponomareva, EV; Selezneva, ND,
)
0.13
" Thus, it can serve as a promising safe adjuvant platform that can help to protect against pandemics and future infectious threats."( Ionic-Liquid-Based Safe Adjuvants.
Angsantikul, P; Cu, K; Curreri, A; Goetz, M; Lahann, J; Mitragotri, S; Tanner, EEL; Ukidve, A, 2020
)
0.56
" Fourteen patients (22%) dropped out for reasons including consent withdrawal (n = 9), adverse reactions (n = 4), and stroke (n = 1)."( Efficacy and Safety of the Association of Nimodipine and Choline Alphoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD Trial.
Chiti, G; Donnini, I; Fierini, F; Melone, A; Pantoni, L; Pescini, F; Poggesi, A; Rinnoci, V; Salvadori, E; Squitieri, M; Tudisco, L, 2021
)
0.62
"Taken together, our data suggest that α-GPC can have a role in neuroprotection in the course of toxic challenges with Aβ."( Beneficial Effects of Choline Alphoscerate on Amyloid-β Neurotoxicity in an In vitro Model of Alzheimer's Disease.
Bernardini, R; Burgaletto, C; Cantarella, G; Di Benedetto, G; Munafò, A, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
" Choline alfoscerate is a precursor in the biosynthesis of brain phospholipids and increases the bioavailability of choline in nervous tissue."( Oral choline alfoscerate counteracts age-dependent loss of mossy fibres in the rat hippocampus.
Amenta, F; Bronzetti, E; Ricci, A; Vega, JA, 1992
)
0.28
" Treatment with choline alfoscerate, a precursor in the biosynthesis of brain phospholipids which increases bioavailability of choline in the nervous tissue, noticeably reduced the loss of Purkinje and granule neurons in rats of 24 months."( Age-related structural changes in the rat cerebellar cortex: effect of choline alfoscerate treatment.
Amenta, F; Del Valle, M; Vega, JA; Zaccheo, D, 1991
)
0.28
" GFC is a precursor in the biosynthesis of brain phospholipids which increases the bioavailability of acetylcholine in the nervous tissue."( Effect of ipsilateral lesioning of the nucleus basalis magnocellularis and of L-alpha-glyceryl phosphorylcholine treatment on choline acetyltransferase and acetylcholinesterase in the rat fronto-parietal cortex.
Amenta, F; Bronzetti, E; Felici, L, 1993
)
0.29
" Treatment with choline alphoscerate, which is a precursor in the biosynthesis of brain phospholipids that increases the bioavailability of acetylcholine in the nervous tissue, restored, in part, the density and pattern of sulphide-silver positive fibres in the fronto-parietal cortex and in the hippocampus."( Nucleus basalis magnocellularis lesions decrease histochemically reactive zinc stores in the rat brain: effect of choline alphoscerate treatment.
Amenta, F; Bronzetti, E; Ricci, A; Sagratella, S; Scotti de Carolis, A; Zaccheo, D, 1995
)
0.29
" This approach may allow for effective, untargeted in-home fortification of complementary foods with low amounts of highly bioavailable iron."( Optimization of a phytase-containing micronutrient powder with low amounts of highly bioavailable iron for in-home fortification of complementary foods.
de Pee, S; Egli, I; Hurrell, RF; Troesch, B; Zeder, C; Zimmermann, MB, 2009
)
0.35
" From the above findings, it is evident that STZ-diabetes has an adverse effect on sperm maturation, which may be due to the decrease in the bioavailability of testosterone and epididymal secretory products."( Impact of experimental diabetes and insulin replacement on epididymal secretory products and sperm maturation in albino rats.
Balasubramanian, K; Malini, T; Rengarajan, S; Singh, S, 2009
)
0.35
" However, their clinical applications face challenges because of short half-life, poor bioavailability and growing drug resistance."( Liposomes of dimeric artesunate phospholipid: A combination of dimerization and self-assembly to combat malaria.
Du, Y; Ismail, M; Li, X; Ling, L; Yao, C, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" Blood levels of DEA reflected the dosing method used; oral greater than dermal with access greater than dermal without access."( Potential mechanisms of tumorigenic action of diethanolamine in mice.
Bartels, MJ; Brzak, KA; Mar, M; Markham, DA; Stott, WT; Thornton, CM; Zeisel, SH, 2000
)
0.31
" B6C3F1 mice were dosed dermally with DEA (0, 10, 20, 40, 80, and 160 mg/kg) for 4 weeks (5 days/week)."( Diethanolamine induces hepatic choline deficiency in mice.
Gamsky, EA; Hicks, SM; Lehman-McKeeman, LD; Mar, MH; Vassallo, JD; Zeisel, SH, 2002
)
0.31
" Our findings are particularly relevant due to the increasing use and higher dosing of statin medications."( Elevated skeletal muscle phosphodiesters in adults using statin medications.
Delano, MC; Meyer, RA; Slade, JM, 2006
)
0.33
" A main group (20 patients) received cereton (choline alfoscerate) as an add-on drug in dosage 1000mg/day intravenous in drops."( [Efficacy of cereton in the acute period of ischemic stroke].
Gaĭfutdinov, RT; Ismagilov, MF; Kuz'mina, IA; Strakhova, TM; Vasilevskaia, OV, 2009
)
0.35
"Forty patients were included in the study: 20 patients of main group received cereton in dosage 1000 mg intramuscular during 15 days and 20 patients of control group received placebo."( [The use of cereton in the rehabilitation of patients with hemorrhagic stroke].
Buĭlova, TV; Glotova, ME; Khalak, ME; Vashkevich, VV, 2009
)
0.35
" Cereton was used in 40 patients (main group) in dosage 1000 mg, piracetam - in 20 patients (control group) in dosage 2000 mg."( [Efficacy and tolerability of choline alphoscerate (cereton) in patients with Parkinson's disease with cognitive disorders].
Anikina, MA; Batukaeva, LA; Iunishchenko, NA; Levin, OS, 2009
)
0.35
" Dosing of dogs with up to 3000 mg/kg AGPC resulted only in reduced activity."( Safety assessment of AGPC as a food ingredient.
Brownawell, AM; Carmines, EL; Montesano, F, 2011
)
0.37
" Increasing intake of α-GPC was associated with a higher risk for total stroke in a dose-response manner."( Association of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years.
Chang, J; Choi, D; Choi, S; Jeong, S; Kim, K; Kim, SM; Lee, G; Park, SM; Son, JS, 2021
)
0.95
"In this cohort study, use of α-GPC was associated with a higher 10-year incident stroke risk in a dose-response manner after adjusting for traditional cerebrovascular risk factors."( Association of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years.
Chang, J; Choi, D; Choi, S; Jeong, S; Kim, K; Kim, SM; Lee, G; Park, SM; Son, JS, 2021
)
0.95
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (10 Product(s))

Product Categories

Product CategoryProducts
Weight Management1
Professional Supplements3
Active Lifestyle & Fitness3
Vitamins & Supplements1
Herbs, Botanicals & Homeopathy1
Pet Supplies1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Cymbiotika Plant Protein Powder Vanilla -- 30 ozCymbiotikaWeight Management Lipase, Alanine, Arginine, Aspartic Acid, Cellulase, Cystine, Vitamin E, Vitamin E, L-Glutamine, Alpha GPC, Glycine, Histidine, Isoleucine, Leucine, Lysine, Methionine, Niacin, Phenylalanine, Phosphorus, Proline, Serine, Threonine, Tryptophan, Tyrosine, Valine, Vitamin K2024-11-29 10:47:42
Designs for Sport GPC Liquid - NSF Certified for Sport -- 2 fl ozDesigns for SportProfessional SupplementsGlycerophosphocholine2024-11-29 10:47:42
Force Factor Forebrain® Advanced Memory & Recall Support -- 60 Vegetable CapsulesForce FactorActive Lifestyle & FitnessAlpha-GPC, Niacin, Pantothenic Acid, Vitamin B6, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Klean Athlete Klean Focus - NSF Certified for Sport -- 90 Vegetarian CapsulesKlean AthleteProfessional SupplementsBiotin, Alpha-GPC, microcrystalline cellulose, calcium carbonate, Lutein, Alpha Lipoic Acid2024-11-29 10:47:42
Momentous Alpha GPC - Informed Sport Certified - 60 Servings -- 60 CapsulesMomentousProfessional SupplementsAlpha-Glyceryl Phosphoryl Choline, Microcrystalline cellulose2024-11-29 10:47:42
Nutrex Research Hemo-Rage Unleashed Fruit Punch -- 30 ServingsNutrex ResearchActive Lifestyle & FitnessTheacrine, citric acid, acesulfame potassium, acesulfame potassium, Betaine Anhydrous, Caffeine Anhydrous, citric acid, Alpha GPC, malic acid, N-Acetyl-L-Tyrosine, Taurine, sucralose2024-11-29 10:47:42
Olly Laser Focus - Berry Tangy Tangerine -- 36 GummiesOllyVitamins & SupplementsCitric Acid, Citric Acid, Alpha GPC, Vitamin B6, Cane Sugar, Vitamin B12, Vitamin B62024-11-29 10:47:42
Plant People WonderFocus Mushroom Gummies Juicy Citrus -- 60 GummiesPlant PeopleHerbs, Botanicals & Homeopathycitric acid, citric acid, Alpha GPC, maltitol, Vitamin B6, Vitamin B12, Vitamin B62024-11-29 10:47:42
Type Zero Clean Alpha GPC -- 600 mg - 90 CapsulesType ZeroActive Lifestyle & FitnessAlpha GPC, stearic acid2024-11-29 10:47:42
Zesty Paws Senior Advanced Cognition Bites Dogs Chicken -- 90 Soft ChewsZesty PawsPet Suppliescitric acid, citric acid, Alpha-GPC, powdered cellulose, Ashwagandha2024-11-29 10:47:42

Roles (6)

RoleDescription
parasympatholyticAny cholinergic antagonist that inhibits the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the muscarinic antagonists.
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
glycerophosphocholineThe glycerol phosphate ester of a phosphocholine. A nutrient with many different roles in human health.
sn-glycerol 3-phosphates
phosphocholinesAny compound having phosphocholine as part of its structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (13)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Phospholipid metabolism12242
Glycerophospholipid biosynthesis7439
Hydrolysis of LPC34
PI Metabolism4911
Glycerophospholipid catabolism77
phosphatidylcholine resynthesis via glycerophosphocholine07
phytate degradation II06
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
16p11.2 proximal deletion syndrome039
phosphatidylcholine resynthesis via glycerophosphocholine310
plasmalogen degradation28
phosphatidylcholine biosynthesis VII22
phytate degradation II011

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency0.56230.044717.8581100.0000AID485294
USP1 protein, partialHomo sapiens (human)Potency0.56230.031637.5844354.8130AID743255
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency100.00000.425612.059128.1838AID504891
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
DNA polymerase kappa isoform 1Homo sapiens (human)Potency100.00000.031622.3146100.0000AID588579
survival motor neuron protein isoform dHomo sapiens (human)Potency35.48130.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (891)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990372 (41.75)18.7374
1990's188 (21.10)18.2507
2000's114 (12.79)29.6817
2010's166 (18.63)24.3611
2020's51 (5.72)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 58.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index58.34 (24.57)
Research Supply Index6.88 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index198.00 (26.88)
Search Engine Supply Index4.00 (0.95)

This Compound (58.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials43 (4.63%)5.53%
Trials0 (0.00%)5.53%
Reviews39 (4.20%)6.00%
Reviews0 (0.00%)6.00%
Case Studies1 (0.11%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other846 (91.07%)84.16%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]